430 related articles for article (PubMed ID: 29858674)
1. Molecular Subtypes of Prostate Cancer.
Arora K; Barbieri CE
Curr Oncol Rep; 2018 Jun; 20(8):58. PubMed ID: 29858674
[TBL] [Abstract][Full Text] [Related]
2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
Wadosky KM; Koochekpour S
Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
[TBL] [Abstract][Full Text] [Related]
4. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
5. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
6. Emerging Variants of Castration-Resistant Prostate Cancer.
Vlachostergios PJ; Puca L; Beltran H
Curr Oncol Rep; 2017 May; 19(5):32. PubMed ID: 28361223
[TBL] [Abstract][Full Text] [Related]
7. Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness.
Schiewer MJ; Knudsen KE
Urol Clin North Am; 2021 Aug; 48(3):339-347. PubMed ID: 34210489
[TBL] [Abstract][Full Text] [Related]
8. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
Liu D; Augello MA; Grbesa I; Prandi D; Liu Y; Shoag JE; Karnes RJ; Trock BJ; Klein EA; Den RB; Demichelis F; Davicioni E; Sboner A; Barbieri CE
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998599
[TBL] [Abstract][Full Text] [Related]
9. Biological Evolution of Castration-resistant Prostate Cancer.
Davies A; Conteduca V; Zoubeidi A; Beltran H
Eur Urol Focus; 2019 Mar; 5(2):147-154. PubMed ID: 30772358
[TBL] [Abstract][Full Text] [Related]
10. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
Shafran JS; Andrieu GP; Györffy B; Denis GV
Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
[TBL] [Abstract][Full Text] [Related]
12. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
13. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications.
Pisano C; Tucci M; Di Stefano RF; Turco F; Scagliotti GV; Di Maio M; Buttigliero C
Crit Rev Oncol Hematol; 2021 Jan; 157():103185. PubMed ID: 33341506
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
15. Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer.
Kang N; Xue H; Lin YY; Dong X; Classen A; Wu R; Jin Y; Lin D; Volik S; Ong C; Gleave M; Collins C; Wang Y
Cancer Gene Ther; 2023 Oct; 30(10):1382-1389. PubMed ID: 37452083
[TBL] [Abstract][Full Text] [Related]
16. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
17. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
18. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
19. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
20. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.
Nyquist MD; Dehm SM
Horm Cancer; 2013 Apr; 4(2):61-9. PubMed ID: 23307762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
